Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia : vimarsana.com

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Dublin , Ireland , United States , Massachusetts , Waltham , Ohio , Athlone , Westmeath , American , Ron Grunstein , Sandy Coombs , Gretchen Murphy , Craig Hopkinson , American Academy Of Sleep Medicine , Circadian Research , Research Development At Alkermes , Alkermes , Woolcock Institute Of Medical Research , Nasdaq , Exchange Commission , Clinically Meaningful , Statistically Significant Improvements , Mean Sleep Latency , All Doses Tested , Both Narcolepsy Type , Idiopathic Hypersomnia , Generally Well Tolerated , Dose Dependent Effects , Wakefulness Test , Woolcock Institute , Chief Medical Officer , Executive Vice President , Sustained Attention , Response Task , Private Securities Litigation Reform Act , Annual Report , Multiple Sleep Latency Test , American Academy , Selective Orexin Receptor ,